Correction To: GLP-1RAs in Type 2 Diabetes: Mechanisms That Underlie Cardiovascular Effects and Overview of Cardiovascular Outcome Data

Cardiovascular Diabetology - United Kingdom
doi 10.1186/s12933-019-0825-1
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Lessons From a Cardiovascular Outcome Trial With Liraglutide in Type 2 Diabetes

Journal of Diabetes Investigation
Internal MedicineEndocrinologyMetabolismMedicineDiabetes
2017English

Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Type 2 Diabetes and Cardiovascular Risk Factors

Current Medical Research and Opinion
Medicine
2011English

Postprandial Dysmetabolism and Cardiovascular Disease in Type 2 Diabetes

Postgraduate Medical Journal
Medicine
2005English

Cardiovascular Risk in Patients With Type 2 Diabetes

CMAJ
Medicine
2005English

Molecular Clocks, Type 2 Diabetes and Cardiovascular Disease

Diabetes and Vascular Disease Research
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2008English

Sulfonylureas and Cardiovascular Complications of Type 2 Diabetes Mellitus

Diabetes Mellitus
Internal MedicineEndocrinologyMetabolismDiabetes
2013English

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus

Cureus
2017English

Contribution of Non Traditional Cardiovascular Risk Factors to the Cardiovascular Disease in Patient With Type 2 Diabetes

Zagazig University Medical Journal
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy